The Skill to Heal. The Heart to Care.

Phone: 505.842.8171

dotAfter Hours: 505.857.3877

dotPharmacy: 505.822.3911




Latest Cancer News

Depression in Cancer Patients: What We Are Missing and What Can Be Done (09-2-2014)

Major depression is an important complication of cancer that can result in additional impairment of quality of life.  A series of three articles published in the Lancet presented new research on depression in people with cancer and confirmed that depression... Continue Reading

Interim Results of X-396 in ALK positive Non-Small Cell Lung Cancer Appear Promising (08-29-2014)

Preliminary results from a small phase 1 study of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor showed that X-396 is well tolerated and has antitumor activity in patients with ALK positive non-small cell lung cancer (NSCLC). Lung cancer is... Continue Reading

Risk of Breast Cancer Recurrence Doesn’t Increase with TNF Inhibitor Use (08-28-2014)

According to the results of a recently published study from Swedish investigators treatment with tumor necrosis factor inhibitors (TNF) does not appear to increase the rate of breast cancer recurrence among patients with rheumatoid arthritis (RA).  The... Continue Reading

Advaxis and Merck Form Collaboration to Evaluate Investigational Combination of Two Novel Immunotherapy Candidates for Advanced Prostate Cancer (08-27-2014)

Advaxis, Inc.a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration agreement with Merck to evaluate the safety and efficacy of ADXS-PSA as monotherapy and in combination with pembrolizumab... Continue Reading

Doctors find that Cholesterol Lowering Statin Drugs may Improve Survival From Colon Cancer (08-26-2014)

According to a new U.K. study, statins, which are widely used cholesterol-lowering drugs, appear to improve colon cancer survival.  The study found that overall, colon cancer patients who took statins such as Lipitor and Zocor had a 29 percent lower... Continue Reading

FDA Approves New Treatment Options for Low Grade Lymphomas and Chronic Lymphocytic Leukemia (08-25-2014)

Gilead Sciences has confirmed FDA approval of Zydelig (idelalisib) for relapsed chronic lymphocytic leukemia (CLL), follicular lymphoma (FL) and small lymphocytic lymphoma (SLL). Non-Hodgkin’s lymphoma (NHL) is a form of cancer that begins in the cells... Continue Reading

Risks May Outweigh Benefits in Surveillance Screening of Elderly with Colon Cancer History (08-22-2014)

In a recent study published in the Journal of the American Medical Association Internal Medicine, researchers reported that patients over 75 with a history of colon polyps or cancer undergoing surveillance colonoscopies are at an increased risk for post-procedure... Continue Reading

Velcade Approved for Retreatment in Multiple Myeloma (08-21-2014)

The U.S. Food and Drug Administration (FDA) has approved Velcade® (bortezomib) for the retreatment of adult patients with multiple myeloma who had previously responded to Velcade therapy and relapsed at least six months following completion of prior... Continue Reading

Aromasin is New Treatment Option for Young Women With Hormone-sensitive Breast Cancer (08-19-2014)

The results of a recently completed clinical study presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and now published online in the New England Journal of Medicine demonstrate that Aromasin® (exemestane), is... Continue Reading

Scientific Review Suggests Aspirin Significantly Cuts Cancer Rates (08-18-2014)

A recent review of several studies confirms that taking a small daily dose of aspirin significantly reduces the risk of developing – or dying from several kinds of cancer.(1) Several clinical studies have suggested that aspirin can reduce the risk... Continue Reading

Weighing the Risks (08-12-2014)

Exploring the Link Between Obesity and Cancer By Kari Bohlke, ScD “For the great majority of Americans who do not use tobacco, weight control, dietary choices, and levels of physical activity are the most important modifiable determinants of cancer... Continue Reading

Large Independent Validation Study Validates Oncotype DX Prostate Cancer Test (08-11-2014)

Genomic Health, Inc. announced positive preliminary results from an additional independent clinical validation study conducted by the Center for Prostate Disease Research (CPDR) demonstrating that the Oncotype DX® Genomic Prostate Score (GPS) predicts... Continue Reading

Next Page »